OSI licenses diabetes drug to Lilly in $385M pact
OSI has licensed the exclusive rights to PSN010--its early-stage diabetes drug--to Eli Lilly for $25 million up front and up to $360 million in milestones plus royalty payments. The drug is designed to fight type 2 diabetes by promoting glucokinase, a protein that prompts the pancreas to make more insulin while promoting better control of glucose.
David Moller, M.D., Lilly's vice president, endocrine and cardiovascular research and clinical investigation commented: "This in-licensing agreement will help bolster Lilly's early stage pipeline and will augment one of our core therapeutic areas.
- here's the report on the pact from Newsday
- and here's the release
Related Articles:
OSI looks to unload Macugen, exit eye diseases. Report
OSI grants licensing rights to Bristol-Myers. Release
Lilly to Icos: Merry Christmas, you're fired. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
